Christopher M. Bearden

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1

Carlos Alexandre Vieira, Avinash Kumar Ágarwal, Benita K. Book et al. · Transplantation · 2004 · 268 citations

Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174

Christopher M. Bearden, Avinash Kumar Ágarwal, Benita K. Book et al. · American Journal of Transplantation · 2005 · 91 citations

Secondary Antibody Response, Host Response, Microbial Pathogens +11

In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody

Richard A. Sidner, Benita K. Book, Avinash Kumar Ágarwal et al. · Human Antibodies · 2004 · 86 citations

Cell Therapy, Vivo Depletion, Immunology +19

Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab

Christopher M. Bearden, Avinash Kumar Ágarwal, Benita K. Book et al. · Human Immunology · 2004 · 62 citations

Cytotoxic Crossmatching, Pronase Treatment, Medicine +10

New Crossmatch Technique Eliminates Interference by Humanized and Chimeric Monoclonal Antibodies

Benita K. Book, Avinash Kumar Ágarwal, A.B. Milgrom et al. · Transplantation Proceedings · 2005 · 42 citations

Immunocytochemical Technique, Allergy, Autoimmune Disease +10